Baron AT - Search Results

1

Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer.

Baron AT, Wilken JA, Haggstrom DE, Goodrich ST, Maihle NJ. Baron AT, et al. IDrugs. 2009 May;12(5):302-8. IDrugs. 2009. PMID: 19431095 Review.

2

Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.

Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ. Baron AT, et al. Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18. doi: 10.1158/1055-9965.EPI-04-0423. Cancer Epidemiol Biomarkers Prev. 2005. PMID: 15734951

3

Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.

Baron AT, Cora EM, Lafky JM, Boardman CH, Buenafe MC, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ. Baron AT, et al. Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):103-13. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 12582019

4

Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole.

Lafky JM, Baron AT, Cora EM, Hillman DW, Suman VJ, Perez EA, Ingle JN, Maihle NJ. Lafky JM, et al. Among authors: baron at. Cancer Res. 2005 Apr 15;65(8):3059-62. doi: 10.1158/0008-5472.CAN-05-0067. Cancer Res. 2005. PMID: 15833834

5

Nadir CA125 concentration as a prognostic indicator in ovarian cancer.

Baron AT, Maihle N. Baron AT, et al. Nat Clin Pract Oncol. 2005 Jun;2(6):288-9. doi: 10.1038/ncponc0178. Nat Clin Pract Oncol. 2005. PMID: 16264982 No abstract available.

6

Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.

Lafky JM, Wilken JA, Baron AT, Maihle NJ. Lafky JM, et al. Among authors: baron at. Biochim Biophys Acta. 2008 Apr;1785(2):232-65. doi: 10.1016/j.bbcan.2008.01.001. Epub 2008 Feb 7. Biochim Biophys Acta. 2008. PMID: 18291115 Review.

7

Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.

Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ. Narayan M, et al. Among authors: baron at. Cancer Res. 2009 Mar 15;69(6):2191-4. doi: 10.1158/0008-5472.CAN-08-1056. Epub 2009 Mar 10. Cancer Res. 2009. PMID: 19276389

8

Soluble epidermal growth factor receptor: a biomarker of epithelial ovarian cancer.

Baron AT, Lafky JM, Boardman CH, Cora EM, Buenafe MC, Liu D, Rademaker A, Fishman DA, Podratz KC, Reiter JL, Maihle NJ. Baron AT, et al. Cancer Treat Res. 2009;149:189-202. doi: 10.1007/978-0-387-98094-2_9. Cancer Treat Res. 2009. PMID: 19763437 Review. No abstract available.

9

Identification of immunoreactive regions of homology between soluble epidermal growth factor receptor and α5-integrin.

Wilken JA, Baron AT, Foty RA, McCormick DJ, Maihle NJ. Wilken JA, et al. Among authors: baron at. Biochemistry. 2011 May 24;50(20):4309-21. doi: 10.1021/bi200126j. Epub 2011 Apr 27. Biochemistry. 2011. PMID: 21491912 Free PMC article.

10

EGFR/HER-targeted therapeutics in ovarian cancer.

Wilken JA, Badri T, Cross S, Raji R, Santin AD, Schwartz P, Branscum AJ, Baron AT, Sakhitab AI, Maihle NJ. Wilken JA, et al. Among authors: baron at. Future Med Chem. 2012 Mar;4(4):447-69. doi: 10.4155/fmc.12.11. Future Med Chem. 2012. PMID: 22416774 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36 results

Search Page

Filters